These observations indicate that IGF-1 LR3 may exhibit superior anabolic actions under specific experimental conditions, although this is not uniformly seen across all measured parameters
Accordingly, incretin-based therapies, such as DPP-4 inhibitors and GLP-1 receptor agonists (GLP-1 RAs) that are resistant to degradation by DPP-4, have been introduced in the market within the past decade to overcome and extend the short half-life of the incretin effect

Three million members of CVS Caremarks clients now enjoy access to clinical weight loss program with proven results, high satisfaction WOONSOCKET, R.I., March 14, 2025 CVS Health (NYSE: CVS) released compelling data today from the CVS Weight Management TM program in which participants achieved more than 15% weight loss on average, including existing anti-obesity medication users who succeeded in nearly doubling their pre-program weight loss while working with program clinicians on diet and lifestyle.* Before enrolling in the CVS Weight Management program, 70% of members were using a weight management drug without any lifestyle or nutrition support.* The initial results demonstrate improved weight loss and high program satisfaction for CVS Caremark clients' plan members trying a lifestyle-first approach and additional clinical effectiveness and cost savings for members receiving clinical support while taking weight management medications like GLP-1s

AOD-9604 is one of the cleanest tools in the peptide world for addressing exactly that
Along with alternative approaches, such as protein-protein interaction inhibitors (Richardson et al